Soon after unveiling positive trial data from a study of its Parkinson's drug candidate, Switzerland's Addex says it plans to ax 28 staffers in Geneva. "We are implementing these strategic initiatives from a position of strength following our recent positive results in Parkinson's disease levodopa-induced dyskinesia Phase II clinical trials," says CEO Bharatt Chowrira. "We believe that these measures will position Addex for long-term success and help build significant shareholder value." Release